Niktimvo (axatilimab-csfr) / Incyte, UCB, Syndax Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Niktimvo (axatilimab-csfr) / Syndax Pharma, Incyte
NCT03238027: A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Checkmark Trial initiation in combination with SNDX-6352
Sep 2017 - Sep 2017: Trial initiation in combination with SNDX-6352
Completed
1
45
US
Axatilimab, SNDX-6352, Durvalumab, MEDI4736
Syndax Pharmaceuticals
Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
11/20
11/20
NCT06488378: Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Recruiting
1
20
NA
Axatilimab, SNDX-6352, Ab969.g2, C24H23FN4O3, Olaparib, Lynparza, AZD2281, KU-005943
Dana-Farber Cancer Institute, Incyte Corporation
Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
09/26
03/29

Download Options